SCHEMBL16197829

SCHEMBL16197829

C[C@@H](O)Cc1ccccc1N

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
ALOX15 P16050 2/20 0.38
CYP3A4 P08684 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.36
ESR1 P03372 1/20 0.36
KCNH2 Q12809 1/20 0.36
NOS2 P35228 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931748 1.00 FDPS (0.39) FDPSGABRA1GABRB2SLC6A2SLC6A4
SCHEMBL5988255 0.84 GABRA1 (0.46) GABRA1GABRB2SLC6A2SLC6A4SLC6A3
SCHEMBL9645646 0.83 FDPS (0.41) FDPSGABRA1GABRB2SLC6A2SLC6A4
SCHEMBL270111 0.82 GABRA1 (0.52) FDPSGABRA1GABRB2SLC6A2SLC6A4
SCHEMBL3068875 0.82 FDPS (0.41) FDPSSLC6A2SLC6A4SLC6A3ALOX15
SCHEMBL18181801 0.82 GABRA1 (0.53) GABRA1GABRB2SLC6A2CYP3A4LMNA
SCHEMBL1225271 0.82 GABRA1 (0.39) GABRA1GABRB2SLC6A2SLC6A4SLC6A3
Butanol SCHEMBL27466867 0.81 TSHR (0.42) FDPSGABRA1GABRB2ALOX15CYP3A4
Butanol SCHEMBL27498308 0.81 TSHR (0.42) FDPSGABRA1GABRB2ALOX15CYP3A4
SCHEMBL31314997 0.80 GABRA1 (0.38) FDPSGABRA1GABRB2ESR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9586913-B2 Processes for the preparation of linezolid using novel intermediates SYMED LABS LIMITED (IN) 2017-03-07 US claimed
US-20160102064-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES SYMED LABS LIMITED (IN) 2016-04-14 US claimed
EP-2989097-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES Symed Labs Limited (IN) 2016-03-02 EP claimed
WO-2014174522-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES SYMED LABS LIMITED (IN) 2014-10-30 WO claimed
US-9586913-B2 Processes for the preparation of linezolid using novel intermediates SYMED LABS LIMITED (IN) 2017-03-07 US disclosed
US-20160102064-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES SYMED LABS LIMITED (IN) 2016-04-14 US disclosed
EP-2989097-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES Symed Labs Limited (IN) 2016-03-02 EP disclosed
WO-2014174522-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES SYMED LABS LIMITED (IN) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102064-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES CYP3A5, SBDS, MLYCD FDPS 1243/4885GABRA1 3132/4885GABRB2 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.